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ABBREVATIONS
AGEs – Advanced glycation end products.
PKC – protein kinase C
12/15-LO - 12/15-lipoxygenase
ROS - reactive oxygen species
FFA - Free fatty acids.
LDL - Low density lipoproteins.
SOD – Superoxide dismutase.
MnSOD - Manganese superoxide dismutase.
Ala16Val – Alanine 16 valine.
C/T - Cytosine/thymine.
MTS - mitochondrial targeting sequence.
RAGE - Receptor for AGE.
(NF)-κB - nuclear factor kappa B.
VCAM-1 - Vascular Cell Adhesion Molecule 1
VEGF - Vascular endothelial growth factor.
DAG – Diacyl glycerol.
SHP-1 - Src homology-2 domain–containing phosphatase-1.
MAPK - Mitogen activated protein kinase.
PDGF - platelet-derived growth factor .
GFAT - glutamine:fructose 6-phosphate amidotransferase .
UDP - GlcNAc- UDP-NAcetylglucosamine.
PAI-1 – Platelet activator inhibitor -1 .
TGF-_1 - Transforming growth factor-1.
VSMC – vascular smooth muscle cells.
PARP - polyADPribose
eNOS – endothelial nitric oxide synthase.
NO – Nitric oxide.
AT1R - Angiotension receptor.
MI – Myocarial infarction.
GPX-1 - glutathione peroxidase .
DM – Diabetes Mellitus.
HYT – Hypertension.
ROS - Reactive oxygen species
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INTRODUCTION
Diabetes mellitus is the most important cause for vascular diseases
of heart and brain. Increased cardiovascular disease risk among diabetic
patients from various racial and ethnic groups have been found by
different studies1 . One of the major causes for death among diabetic
patients includes myocardial infarction and other cardiovascular diseases
which account for about 50% of all diabetes mortalities, and much
morbidity2. Many factors including genetic factors are involved in the
pathophysiology of cardiovascular disease in diabetes. The combining
factor in the development of diabetic complications is oxidative stress3.
Oxidized LDL results in atherosclerotic plaque 4 formation that leads to
vascular complications. It is a fact that among diabetics some develop
vascular complications but not seen in others.This may be due to presence
of some gene polymorphism in those developing complications. Gene
polymorphisms in antioxidant enzymes like superoxide dismutase and
catalase in diabetes has been reported 5. This polymorphism results in
decrease in level and activity of antioxidant enzymes which leads on to
oxidative stress. This increase in oxidative stress can lead on to
atherothrombotic complications. A polymorphism in superoxide
dismutase 2 gene which changes the secondary structure of
9
mitochondrial targeting sequence of the manganese superoxide dismutase
enzyme is seen. This polymorphism is present in exon 2 of the gene
where normal GCT is mutated to GTT. This results in creation of a
restriction site(rs 4880) as well as change of aminoacid from alanine to
valine at 16th position. This enzyme otherwise called as manganese
superoxide dismutase is present inside mitochondria. This polymorphism
in mitochondrial targeting sequence of the enzyme causes impaired
targeting of the SOD 2 enzyme resulting in reduced activity of the
enzyme inside mitochondria. A study has shown that individuals with this
polymorphism had thickened carotid wall making them prone for cardiac
complications. 6 . This polymorphism causes defective targeting of
superoxide dismutase to mitochondria where it is required to combat
oxidative stress, which can lead to development of oxidized LDL and
accelerated foam cell formation in atherosclerosis7.
This polymorphism is also supposed to be related with cancers of
breast 8, lung 9, Parkinsons disease10 , anterior uveitis11. Milan Flekac et al
showed a positive association between mitochondrial superoxide
dismutase gene polymorphism and vascular complications in diabetes.
10
This study is done to find out if this polymorphism is associated
with cardiovascular complications in diabetes, and to correlate it with
superoxide dismutase activity.
11
REVIEW OF LITERATURE
Diabetes Mellitus is a heterogeneous disease characterized by
defective synthesis and/or secretion of insulin, as well as by resistance of
the peripheral tissues to the hormone activity.
Globally around 100 million people suffer from diabetes. By 2025,
it is supposed to rise to 300 million. As per 2011 statistics, there are about
61 million diabetic patients in India12. The mortality rate of diabetes in
India is just less than a million in 201113.
Many etiological factors are considered to be responsible for
diabetic micro- and macroangiopathy where persistent hyperglycemia
plays the leading part 14 .There is a 3- to 8- fold increased risk of
cardiovascular disease among patients with diabetes and impaired glucose
tolerance. About one third of patients with acute myocardial infarction
have diabetes and another one third have impairment of glucose
tolerance15.
Atherosclerosis is the main risk factor for cardiac problem in
diabetes mellitus 16 . There are various risk factors for atherosclerosis,
some of which are unmodifiable like age, male sex, socioeconomic status
and some of which are modifiable like Insulin resistance &
12
hyperglycemia, cigarette smoking, alcoholism, obesity, oxidative stress,
hypertension.
Oxidative stress is the main cause of atherosclerosis and other
diseases such as cancers, rheumatic arthritis, haematological and
neurodegenerative disorders and diabetes mellitus 17 .The free radical
concentration in the body increases either due to elevated production or
deficent removal due to deficiency of scavenging enzymes. Oxidative
stress causes diabetes as well as its micro and macrovascular diseases
due to diabetes.18.
PATHOPHYSIOLOGY OF DIABETIC VASCULAR DISEASE
The key factors contributing to atherosclerosis and plaque rupture
in diabetes 19 include
1. Endothelial dysfunction and vascular smooth muscle cell
dysfunction.
2. Dyslipidemia.
3. Thrombogenic state.
All these abnormalities occur in diabetes due to oxidative stress
caused by hyperglycemia and insulin resistance.
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One of the major mechanisms for development of diabetic vascular
complications is oxidative stress by superoxide anion. Increased
superoxide production in diabetes occurs due to hyperglycemia inside
cells or high free fatty acid levels in endothelial cells. High FFA level in
diabetes is due to insulin resistance causing increased FFA release from
adipocyte which move in to endothelial cells.
Hyperglycemia and high FFA in diabetes causes tissue and
endothelial cell injury by various ways.
(1) activation of polyol pathway due to hyperglycemia.
(2) damage by elevated production of advanced glycation end products.
(3) Stimulation of protein kinase C enzyme
(4) Augmented formation of hexosamines20.
(5) Stimulation of the 12/15-lipoxygenase (12/15-LO) enzyme21 .
These pathways are commonly stimulated by increased synthesis
of superoxide inside mitochondria22
14
This elevated synthesis of superoxide radical occurs due to
hyperglycemia and high FFA levels which in turn activate all the
mechanisms of complications as shown in figure 1.
Figure 1
Hyperglycemia in diabetes causing oxidative stress and
activating damaging pathways of complications.
The high levels of glucose and FFA in diabetic cells and endothelial cells
result in more glucose and FFA getting burnt in citric acid cycle. This
causes increased transfer of reducing equivalents in the respiratory chain.
This results in increase in the electrical potential until up to a level when
there is inhibition of third complex of electron transport chain23. This
results in reversal of transfer of electrons from third complex to
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coenzyme Q which in turn gives it to oxygen producing
superoxideanion ,(Fig. 2). This superoxide is dismutated by manganese
superoxide dismutase enzyme present in mitochondria. So patients with
ala 16 val SOD2 gene polymorphism have decreased mitochondrial
superoxide dismutase leading on to increased concentration of superoxide
which activates the damaging pathways.
Figure 2
Microvascular complications in diabetes are also due to
intracellular hyperglycemia. In addition to hyperglycemia, macrovascular
complications are due to elevated fatty acid level caused by insulin
16
resistance. As only specific cell types are affected by generalized
hyperglycemia it seems that affected cells fail to check the glucose entry
during hyperglycemia . When glucose level is high, vascular endothelial
cells exhibit no significant reduction in glucose transport rate, resulting in
intracellular hyperglycemia.24.
Activation of polyol pathway
This mechanism was described in the 1966 Science paper I.The
harmful aldehydes produced in tissues is converted to harmless alcohol
by aldose reductase. However when there is hyperglycemia, there is
increased production of sorbitol from glucose by this enzyme, which
utilizes its coenzyme NADPH 25 . Fig. 3.
Figure 3
Activation of polyol pathway.
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NADPH is essential for synthesis of reduced form of glutathione,
which is needed for the enzyme glutathione peroxidase involved in
reducing free radicals. As NADPH is used up by this polyol pathway,
tissues fail to defend free radical damage. The reactive oxygen species
then damages endothelial cells which may act as initiating factor for
development of atherosclerosis.
Damage by advanced glycation end products
Whenever there is hyperglycemia, there is increased production of
advanced glycation end products. These are produced by spontaneous
reaction between glucose and proteins.
These seem to injure cells by various ways.
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The foremost one is the glycation of proteins inside the cells which
act as transcription factors and coregulators.26
The advanced glycation end products disrupt the communication
between cells and extracellular matrix by altering the proteins forming the
matrix. This results in malfunction of endothelial cells with failure of
normal protective function 33 .
Another way by which advanced glycation end products exert its
effect include the attack of plasma proteins like albumin by the precursors
of advanced glycation end products. The receptors for advanced glycation
end products in endothelial cells get stimulated when they interact with
AGE precursors. This stimulation increases the synthesis of mediators
and growth factors involved in atherosclerotic plaque
formation, .Stimulation of (NF)-κB, resulting in various alteration in gene
expression occurs by the interaction of advanced glycation end products
with its receptors.27.
This interaction also stimulates the transcription of genes coding
for thrombomodulin and other coagulation factors in endothelial cells. It
also induces the transcription of cell adhesion molecules and various
growth factors which bring about adhesion of inflammatory molecules on
to endothelial cells and raised permeability of blood vessels.28See figure 4.
By all these ways advanced glycation end products bring about
atherothrombotic changes in blood vessels.
Increased Protein Kinase C Activation
High levels of ROS inhibit the glyco
3-phosphate dehydrogenase (GAPDH) which in turn leads to enhanced
production of DAG from triose phosphate. This DAG causes excessive
activation of several PKC isoforms
end products with their
pathway with stimulation of isoenzymes of protein kinase C
results in phosphorylation and activation of pathogenic mechanisms.
lytic enzyme glyceraldhyde
29
. The binding of advanced glycation
receptors can result in augmentation of signaling
19
-
30
. This
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It includes increased production of SHP-1 which is a tyrosine
phosphatase enzme.
It also inhibits the signal transduction through platelet derived
growth factor receptor by causing dephosphorylation. This may have
adverse effect on pericytes around endothelium, causing their death31.
Similarly increased fatty acid oxidation plays a significant role in
initiating atherosclerosis by damaging endothelial cells and also cardiac
cells which causes cardiomyopathy.
Increased protein kinase C furthermore results in stimulation of
nuclear factor kappa B which induces many genes involved in
inflammation causing damage to blood vessels.
The consequences of increased blood glucose concentration and
stimulation of protein kinase C32, is shown in fig 5.
Figure 5.
Consequences of hyperglycemia induced
activation of protein kinase
21
Augmented formation of hexosamines
High blood glucose concentration and increased fatty acid level
seen in diabetes results in high levels of fructose-6-phosphate. These then
enter in to the path of aminosugar formation. Both hyperglycemia and
insulin resistance induced excess fatty acid oxidation , increase the flux of
fructose -6-phophate into the hexosamine pathway. Fructose 6-phosphate
is transformed to glucosamine phosphate by amidotransferase which
transfers amino group from glutamine to fructose-6-phosphate. This is
subsequently transformed to UDP-NAcetylglucosamine.
UDP- GlcNAc acts as a source of NAcetylglucosamine which is added to
serine residues present in various proteins, especially those involved in
transcription of genes 33. This especially causes stimulation of genes
22
concerned with atherosclerotic plaque formation. In smooth muscle cells
of blood vessels, N-glycosylation of transcription factor Sp1 results in
switching on of promoter of plasminogen activator inhibitor -1 . Within
endothelial cells, this causes stimulation of plasminogen activator
inhibitor -1 and transforming growth factor-1, which are involved in
pathogenesis of atherosclerosis seen in figure 6.
Figure 6.
Hyperglycemia increases flux through the hexosamine pathway
which plays a role in atherothrombosis
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12/15-lipoxygenase (12/15-LO) pathway
Hyperglycemia promotes the production of lipoxygenase enzymes,
both 12 and 15 isoenzymes. The low density lipoproteins get oxidized by
these enzymes and this oxidized lipoprotein is highly atherogenic than
normal low density lipoproteins. This oxidation mostly occurs in
macrophages. Such type of pathogenic oxidation of low density
lipoproteins are found in endothelial cells as well as smooth muscle
cells34.
12-lipoxgenase causes stimulation of transcription of cell adhesion
molecules like VCAM-1 over the surface of endothelial cells, which
results in binding of endothelium to inflammatory cells including
macrophages.
24
It as well causes increased transcription of proteins present in
extracellular matrix, inflammatory chemokines which attract
inflammatory mediators to endothelium. Moreover, it has been shown to
cause augmented growth of vascular smooth muscle cells. See figure 7.
Figure 7.
Actions of 12/15-LO in the vessel wall
Certain studies concluded that, if superoxide radical was destroyed
by manganese superoxide dismutase enzyme, the high blood glucose
concentration was unable to stimulate the damaging mechanisms35 . This
has been verified by conducting research in mice which were genetically
altered to produce increased concentration of manganese superoxide
dismutase enzyme.
25
Augmented superoxide synthesis inside mitochondria by increased
blood glucose level stimulates the various detrimental mechanisms
by inactivating glyceraldheyde -3-phosphate dehydrogenase enzyme.
When the glyceraldheyde -3-phosphate dehydrogenase enzyme
becomes inactivated by increased mitochondrial superoxide production,
there is accumulation of previous products in reaction of glycolysis.
Each accumulated intermediate of glycolysis pathway causes
stimulation of each one of the detrimental pathways. figure 8.
Figure 8.
Hyperglycemia causing activation of damaging pathways by
inhibition of GAPDH(Glyceraldehyde-3-phosphate dehydrogenase).
1. Increase in glyceraldehydes 3 phosphate activates AGE pathway by
forming methylglyoxal from glyceraldehyde-3 phosphate.
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2. Formation of diacylglycerol from glyceraldehyde-3 phosphate
activates PKC pathway.
3. Increase in fructose -6 phosphate results in formation of UDP–
Nacetylglucosamine by the enzyme GFAT activating hexosamine
pathway.
4. Activation of the polyol pathway , due to reduction of glucose by
aldose reductase ,which utilizes NADPH,therby causing depletion
of NADPH.
Augmented superoxide synthesis inside mitochondria by increased
blood glucose level inactivates glyceraldheyde -3-phosphate
dehydrogenase enzyme by causing stimulation of poly(ADPribose)
polymerase36 as seen in figure 9.
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Figure 9
Hyperglycemia-induced mitochondrial superoxide production
inhibits GAPDH by activating poly(ADPribose) polymerase.
Superoxide production by hyperglycemia and fatty acid oxidation
cause DNA strand breaks which activates poly(ADPribose) polymerase
PARP. This PARP then splits NAD in to nicotinic acid and ADP-ribose
which modifies and inhibits GAPDH activity.
Studies show that both manganese superoxide dismutase enzyme
and uncoupling protein-1 can stop these mechanisms from occurring 50.
They have also shown that death of podocytes and damage to
endothelial cells are stopped by use of inhibitors of PARP.
These inhibitors of PARP apoptosis, improved the symptoms of
neuron damage and kidney damage37 .
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In addition to above processes, the augmented free radical
production caused inactivation of the important enzymes needed to
prevent atherogenosis .They include prostocyclin synthase and
endothelial nitric oxide synthase38, .
Catalytic antioxidants
Salvemini D et al found that use of analogues of either superoxide
dismutase or catalase resulted in stoppage of inhibition of the enzyme
prostacyclin synthase by superoxide radical in diabetic animals39.
Hyperglycemic memory
It has been observed that even though the blood glucose level had
been in control for many months, there was still injury occurring to
various cells and tissues. This is known as “hyperglycemic memory”. The
reason can be attributed to epigenetic modifications done by free radical
like superoxide anion. When the level of superoxide anion or
methylglyoxal derived from it was reduced, it completely stopped the
generation of these epigenetic modifications. This has been revealed by
various studies40. So the increased risk of patients for complications with
SOD2 polymorphism can be deduced from this.
29
Studies by Ballinger et al and Semenkovich CF et al in rat model
showed that there is increased formation of atherosclerosis in rats having
insufficient mitochondrial manganese superoxide dismutase enzyme41,.
In transgenic mouse models of cardiovascular disease, favorable
effects of overexpression of antioxidant enzymes had been observed. The
reasonable drug of choice for ameliorating the oxidative stress caused by
hyperglycemia would be analogue of manganese superoxide dismutase
for these experiments.56.
As previously pointed out, the key factors contributing to
atherosclerotic lesions in diabetes include endothelial dysfunction,
dyslipidemia, thrombogenic state. figure 10.
Figure 10
Mechanism of atherosclerosis in diabetes mellitus
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Endothelial dysfunction;
Endothelial cells produce nitric oxide (NO) constitutively to
preserve vascular homeostasis . The role of nitric oxide is to produce
vasodilatation by causing relaxation of VSMC.
Nitric oxide also prevents the movement and hyperplasia of VSMC.
Moreover, it inhibits the binding of endothelial cells to inflammatory
cells and platelets. Nitric oxide also prevents stimulation of nuclear factor
kappa B , which is involved in production of inflammatory mediators
contributing to atherosclerosis 42. All these are caused by activation of
signal transduction pathways by nitric oxide. So nitric oxide acts as a
defensive mechanism against the endogenous injury of endothelium and
atherosclerosis,
Nitric oxide levels are decrease in hyperglycemia, which may be
due to impaired NO production or increased degradation of NO.
Impaired nitric oxide production can be due to following reasons.
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As previously explained, hyperglycemia and free fatty acids lead to
increased superoxide generation which activates PKC pathway which
inturn produces superoxide by activating NADPH oxidase. This
superoxide inactivates NO and converts it into peroxynitrate 43 . The
formed peroxynitrate inhibits tetrahydrobiopterin ,which acts as the
coenzyme for the nitric oxide synthase enzyme, thereby inhibiting nitric
oxide synthase44.
Activation of hexosamine pathway and PKC pathway by
superoxide anion results in inhibition of the enzyme Akt kinase,involved
in activation of nitric oxide synthase enzyme. So this causes reduced
synthesis of nitric oxide45.
Normally, DMA dimethylaminohydrolase is recquired to degrade
ADMA(Asymmetric Dimethyl Arginine), which inhibits nitric oxide
synthase enzyme. But this enzyme is inhibited by the free radical
superoxide anion, resulting in accumulation of ADMA . This
accumulated ADMA inhibits the enzyme nitric oxide synthase46.
Insulin plays an important role in relaxation of blood vessels 47, by
stimulating nitric oxide synthase enzyme through PI-3kinase pathway.
The impaired insulin sensitivity or reduced insulin level seen in
diabetes ,thus causes reduced production of nitric oxide . But the
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stimulation of MAPK by insulin remains unaltered ,which causes various
atherothrombotic changes by altering endothelin levels.
VASCULAR SMOOTH MUSCLE DYSFUNCTION
As already explained, the relaxation of blood vessels by nitric
oxide is reduced in diabetes mellitus. There has also been seen increased
movement and proliferation of VSMC outside the endothelium, resulting
in aggravation of atherosclerotic lesion48. There is moreover augmented
destruction of VSMC in atherosclerotic lesion, which accounts for easy
disintegration of plaque. Elevated synthesis of MMP by inflammatory
mediators result in degradation of collagen found in plaque49.
DYSLIPIDEMIA
One of the precipitating factors for development of atherosclerosis
is high lipid levels. Most of the diabetic patients have abnormal lipid
levels.
The type of low density lipoprotein seen in diabetes is abnormal in
size and density. It is smaller and denser than normal low density
lipoprotein, which allows them to pass through the blood vessel wall and
get adhered to it. From there, they are vulnerable to the attack by free
radicals50.
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This oxidatively modified low density lipoproteins are seen by
leukocytes as alien particles. This results in engulfment of these particles
by white blood cells, initiating the formation of foam cells. These foam
cells cause propagation of macrophages, VSMC 51 , resulting in
development of atherosclerosis.
Also, there is persistence of low density lipoproteins due to
addition of glucose to it, resulting in development of atherosclerosis.
But the defensive effect of high density lipoprotein is lost, when
glucose molecules are added, as it causes early degradation of high
density lipoproteins.52
Hypertriglyceridemia can also lead to increased production of the
small, dense form of LDL and to decreased HDL transport of cholesterol
back to the liver in diabetes53.
Hypertriglyceridemia occurs in diabetes because of reduced
activation of LPL, due to low insulin level which causes reduced
triglyceride breakdown from VLDL and chylomicrons. And also low
levels of insulin results in loss of inhibition of HSL, leading on to high
FFA concentration.
THROMBOTIC STATE
The common final pathology of MI is the disintegration of fibrous
cap leading on to coagulation and blockage of large blood vessel..
Diabetes is a thrombotic state because
and transcription of glycoproteins ,which are involved in binding
to platelets54. There is decreased platelet
superoxide anion formation associated with high intracellular platelet
glucose concentration and
altered in diabetes with release of mediators due to impairment of
calcium homeostasis 56.
In diabetes, there
and reduction of various anti
increased synthesis of PAI
complicating plaque rupture.
Superoxide dismutases
superoxide. The superoxide
Superoxide dismutases (SODs) are the enzymes which play a
primary role against oxidative stress.
there is hyperactivity of platelets
-derived NO, due to increased
PKC activity 55 . Platelet conformation is
is elevation of levels of various clotting factors
clotting factors. 57 ,. Moreover, there is
-1, which results in elevated risk of thrombosis
Superoxide dismutases
, increase the rate of degradation of
is converted to O2 and H2O2.
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of VWF
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Action mechanism
It has 2 reactions.
The first reaction is the one whereby superoxide is converted to
oxygen by oxidation.
In the second reaction, superoxide is reduced to hydrogen
peroxide.58
O2°- + Mn(III)SOD O2 + Mn(II)SOD -------- oxidative reaction
O2°- + 2H+ + Mn(II)SOD  H2O2 + Mn(III)SOD--- reductive reaction
3 isoenzymes of superoxide dismutase are present. They include
1. Superoxide dismutase 1 also called CuZn superoxide
dismutase,present mainly inside cytoplasm. It is also localized
inside nucleus and lysosomes,having a molecular weight of 32,000
Da.
2. Superoxide dismutase 2 also called as Mn superoxide
dismutase ,present inside mitochondria59.
3. Superoxide dismutase 3 ,also called as extracellular SOD having
copper and zinc as its cofactor. It is mainly seen in blood ,also
present in CSF and ascitic fluid. It has four similar subunits ,with
molecular mass of 135
Manganese superoxide dismutase has 4 similar subunits,with each
monomer weighing about 23,000 daltons ( fig 11 )
supposed to have 2 parts, an all alpha amino terminal part and an alpha or
beta carboxy terminal part.SOD2 ha
in scavenging mitochondrial superoxide ,playing a major role in
preventing formation of cancer
Specific areas of superoxide dismutase 2 enzyme seem similar in
different species of animals, thus projecting them to be necessary for
,000 daltons.60
61
. Each monomer is
s been shown to play a important part
10 and in defending hyberbaric oxygen
stimulated lung injury.
Figure 11
Structure of MnSOD
36
37
their catalytic mechanism. Many of them ,especially,histidine at 26th and
81st position and glutamine at 67th and 171th position of Eschericia coli act
as ligands for metal ions. Some of them act as entry point to active site62 .
The manganese forms a coordination complex with 5 groups, 4 of them
being side chains of proteins and the last being either H2O or OH-. (fig 12)
Figure 12
ACTIVE SITE OF MANGANESE SUPEROXIDE DISMUTASE
ENZYME
Structure of manganese superoxide dismutase gene
The human superoxide dismutase 1 gene is found to present in long
arm of 21st chromosome63 . The human superoxide dismutase 3 is found
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to be situated in 4th chromosome 64. The human superoxide dismutase 2
is found to be situated in 25th position of long arm of 6th chromosome65 .
There are about five sequences of exons and four intronic sequences seen
in the manganese superoxide dismutase gene. (see Fig. 13).
Figure 13
Structure of MnSOD gene.
Particularly in humans,there is absence of promoter sequences like
TATA box and CAAT box ,but areas rich in guanine,cytosine residues
with binding sites for activator protein 2 and sp1 is seen66. This enzyme is
produced along with signaling sequence which directs it mitochondria
after its synthesis from mitochondria 67 . Once the enzyme reaches
mitochondria ,the targeting sequence is removed resulting in formation of
active protein68.
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The polymorphism analysed in this study is present in the region
coding for mitochondrial targeting sequence of SOD2 gene 10 . At 1183rd
position of the gene, normally there is cytosine as GCT codon which
codes for alanine. It causes proper conformation of the MTS in to an
alpha helix, which properly targets the enzyme to mitochondria.
Transversion of cytosine to thymine produces GTT codon which codes
for valine instead of normally coded alanine. This causes improper
folding of the MTS in to beta sheet structure, with failure of targeting in
to mitochondria,which also gets destroyed by proteasome. 10 .The
distribution of alanine coding codon among white population seems to be
about 50%, whereas in oriental population ,it is very low of about 13-
30%.,69 . Individuals can have alanine in both the alleles,or valine in both
the alleles,or alanine in one allele,and valine in another allele 11. So this is
a functional polymorphism which is found to be common in this gene.
Some studies have shown that messenger RNA of valine coding gene is
speedily destroyed (Sutton et al., 2005). Polymorphism in the promoter
area of the superoxide dismutase gene has also been proposed to decrease
the transcription of this gene,with resulting decrease in enyme levels in
cancer cell lines. (Xu et al., 1999b)70.
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Another mutation in promoter area of this gene is observed,where
cytosine replaces thymine,causing altered interaction of activator protein
-2,with reduced expression of the enzyme. (Xu et al., 1999b).
Toxic superoxide
Superoxide causes multiple pathological changes within the cell.
SOD protects the cell from superoxide toxicity. One of them
include conversion of nitric oxide to harmful peroxynitrate. Minute levels
of superoxide itself will inhibit TCA cycle enzymes and electron
transport chain. The superoxide anion radical (O2−) spontaneously
dismutes to O2 and hydrogen peroxide (H2O2) quite rapidly (~105 M−1s−1
at pH 7). SOD is necessary because superoxide reacts with sensitive and
critical cellular targets. For example, it reacts the NO radical, and makes
toxic peroxynitrite. The dismutation rate is second order with respect to
initial superoxide concentration.it also causes accumulation of harmful
free iron. 106.
Regulation of superoxide dismutase concentration
It is very important to maintain optimum conentration of
supaeroxide dismutase to combat free radicals,which are constantly being
produced in the body.
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This enzyme seems to be regulated at various levels.
First is at the level of transcription, where numerous transcription
factors are involved in its regulation.
The most important one is the nuclear factor kappa B which
responds rapildly to tissue injury. There has been found response
elements for this transcription factor in both introns and promoter in all 3
isoenzymes of superoxide dismutase.
Superoxide dismutase 1 cannot be stimulated rapidly because it is
synthesised continuosly . But promotor of this gene responds to nuclear
factorκB through phosphotidylinosital-3 kinase pathway and increases its
expression.
The expression of superoxide dismutase 2 is increased quickly by
harmful radiation,iflammatory mediators and certain interferons like IFN-
γ.
AT-II, iflammatory mediators, NO have regulatory role over
transcription of superoxide dismutase 3.
Second important transcription factor is specificity protein 1,which
has zinc finger motif through which it binds nuclear material ,especially
42
in guanine,cytosine rich regions and brings about increased expression of
all 3 superoxide dismutases.
Another transcription factor includes activator protein 1 which has
got fos as well as jun DNA binding domains through which they activate
the genes for superoxide dismutases. Ironiclly,the level of this activator
protein is reduced by excess of the manganese superoxide dismutase
enzyme.
Another transcription factor is activating protein 2,which can
interact with different transcription factors. When this factor bind to
promoter region of superoxide dismutase 2 gene, it prevents stimulation
of expression by specificity protein 1,thereby reducing the transcription
of this gene.
Regulation by epigenetic mechanism
Changes in manganese superoxide dismutase in breast cancer is
attributed to repression of the gene by epigenetic changes such as
methylation. One explanation for the association of atherosclerosis with
superoxide dismutase 3 is due to hypomethylation.
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Modifications after transcription
Stabilty of messenger RNA and ineraction of the messenger RNA
to specific proteins are also important in translation of this trnscripts. Alu
region seen in 3’ untranslated region of the mRNA seems to be targetted
by micro RNA which controls its expression. A RNA binding protein
needs to be bound to this 3’ untranslated region to increase its expression.
Therapeutic use of superoxide dismutase
It has been proved a safe therapeutic agent in animal as well as
human studies. It has been used to treat complications of radiation
following carcinoma of breast. It has also shown improvement in burns
patients,systemic lupus erythematosus,herpes simplex and fibrosis due to
liver damage by hepatitis C and various other diseases.71
It has been considered a potential target of gene therapy. Especially,
gene for manganese superoxide dismutase complexed with either
liposome or with plasmid reduced irradiation related damage in various
carcinomas.
It has also proved benefical in kidney,testes reducing reperfusion
injury following ischemia in rats. Also protection protection against
myocardial infarction and restenosis has been shown.
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So, in future, it has got potential role in traeatment of various
diseases.
Diseases associated with altered MnSOD level
Apart from complications in diabetes,changes in manganese
superoxide dismutase concentration was found to be linked with
degenerative diseases like Parkinson,s disease,CMT disease and DMD72.
Reduced levels of the enzyme has been found in various kinds of
cancer73 .
Other diseases associated with MnSOD gene polymorphism
MnSOD polymorphism and diabetic retinopathy and nephropathy
Retinopathy in diabetes is due to damage to vascular endothelium
by inflammation and high levels of VEGF in vitreous causing blood
vessel proliferation. This occurs due to increased superoxide causing
activation of protein kinase C and other damaging pathways leading on to
inflammation of retinal blood vessels and elevated VEGF production.
This increase in superoxide level may be due to reduced degradation of
superoxide by MnSOD Ala16Val polymorphism74. Studies in japan,korea
have shown linkage between this polymorphism and nephrophathic
changes in diabetes patients75 .
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MnSOD polymorphism and asthma
A study showed that patients with Ala genotype have a greater risk
of asthma than those with Val-Val genotype 76 .The reason is higher
MnSOD activity causes increased production of cytotoxic hydroxyl
radicals and hydrogen peroxide which when acted upon by
myeloperoxidase produces hypochlorous acid that causes cellular damage
in adjacent epithelial cells
The MnSOD −9 Val-Ala/Ala-Ala genotypes were at greater risks of
asthma than those carrying the Val-Val genotype.
MnSOD polymorphism and schizophrenia
One study has observed positive association between this mutation
with schizophrenia and propensity of development of tardive dyskinesia
among these patients 77 . The reason that neurons getting particularly
damaged include reduced concentration of catalase,glutathione
peroxidase,increased oxygen utilization and increased rate of metabolism,
making them prone for oxidative stress.
Another reason they are highly prone for oxidative stress is that the
neuronal membrane is mainly made of polyunsaturated fatty acids,which
rapidly get attacked by reactive oxygen species. This peroxidation
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disrupts many vital functions like ion channels and communication
systems.78
MnSOD polymorphism and anterior uveitis
One study has observed association between anterior uveitis and
polymorphism in manganese superoxide dismutase gene,where there is
transversion of guanine to adenine at position 47. it particularly rises the
propensity of the diseas in persons having HLA-B-2779.
MnSOD polymorphism and breast cancer
In contrary to above said observations that alanine allele is
protective for various diseases, it has been observed in other studies
that,alanine genotype with raised manganese superoxide dismutase is
associated with tumours of colon 80,breast81,lung82 etc.
MnSOD polymorphism was also studied in diseases like
rheumatoid arthritis,bechet’s disease, ovarian cancer,prostate cancer.
Polymorphism in superoxide dismutase 1 and superoxide dismutase
3
About 11 mutations in Cu/Zn SOD or superoxide dismutase 1 has
been found to be associated with amyotrophic lateral sclerosis in a study
performed by Daniel R.Rosen et al.83
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A study conducted in preterm infants found that a polymorphism at
8192287 restriction site of extracellular superoxide dismutase showed a
defensive effect against development of intraventricular hemorrhage. 84
Also a polymorphism in Cu/Zn superoxide dismutase showed a
protective effect against development of retinopathy of
prematurity,respiratory distress syndrome and intraventricular
hemorrhage. Similarly,another mutation in superoxide dismutase 2
showed protective effect against development of retinopathy of
prematurity,respiratory distress syndrome and intraventricular
hemorrhage but showed risk of developing bipolar disorder among
preterm infants.
A study conducted in extracellular superoxide dismutase among
diabetic individuals observed that threonine was more frequent than
alanine at 40th position. Also insulin sensitivity to insulin was low among
diabetic individuals with threonine compared to alanine85.
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AIMS AND OBJECTIVES
Diabetes is a common cause of cardiovascular disease especially in
developing countries. It is a major contributor to mortality among patients
suffering from non-insulin dependant diabetes. Genetic factors make the
diabetic patients prone for cardiovascular complications.The knowledge
of genetic factors of diabetic cardiovascular disease may help in
explaining the molecular basis of this disorder and in designing
prevention and treatment methods. Literature evidences point to the role
of MnSOD gene polymorphism in the causation of cardiovascular
complications in diabetes.
The aim of this study is
1. To analyse if there is increased susceptibility of diabetic patients
with MnSOD gene polymorphism to cardiovascular complications.
This is done by finding out the distribution of MnSOD gene
polymorphism among type 2 diabetic patients with and without
cardiovascular disease and in healthy controls.
2. To assess if this MnSOD polymorphism causes reduced SOD
activity.
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MATERIALS AND METHODS
This is a case-control study conducted after obtaining ethical
committee clearance. This study was conducted in the time interval of
February 2012- August 2012 at Madras medical college and Rajiv Gandhi
government general hospital.
Study population:
CASES:
About 60 diabetic patients with more than five years duration
attending cardiology ward, diabetology ward and outpatient department
were included in the study after obtaining consent and were categorised
into
Group 1A: 30 (14 males, 16 females) type 2 diabetic patients with
cardiovascular disease and
Group 1B: 30 (11 males, 19 females) type 2 diabetic patients
without cardiovascular disease.
The diagnosis is based on clinical history, fasting plasma glucose
levels and ECG findings (pattern of myocardial infarction in case of
Group 1A and normal pattern in case of Group 1B)
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Exclusion criteria:
Patients less than 30 years of age and less than 5 years of duration
of diabetes.
CONTROLS:(Group 2)
30 individuals attending master health check- up were selected as
controls.
Age, sex and other confounding factors like smoking, alcoholism
were matched .
Sample collection:
Blood samples:
Blood was collected after an overnight fast of 8-12 hrs. About 4
mL of blood was drawn from the cubital vein of the subjects. 2 mL was
transferred into a EDTA tubes and another 2ml transferred in to serum
tube.
Serum was used for superoxide dismutase activity. EDTA tube was
centrifuged at 2000 rpm for twenty minutes to get buffy coat for DNA
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extraction and the plasma was used for glucose and lipid profile
estimation.
DNA extraction was done on the same day and extracted DNA
stored at -20°C.
METHODS:
BUFFY COAT SEPARATION
Buffy coat was separated by centrifugation of EDTA tubes at 2000
revolutions per minute for 20 minutes. Buffy coat was transferred to
2mL eppendorf and was used for DNA extraction. Plasma separated was
used for glucose and lipid profile .
Serum superoxide dismutase activity ,plasma triglycerides,plasma
HDL,plasma cholesterol,plasma glucose, were analysed by using kits in
ERBA semiautoanalyser. Low density lipoprotein cholesterol (LDL-c)
was calculated using Friedwald’s formula.
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DNA EXTRACTION BY MODIFIED HIGH SALT METHOD86
RBC Lysis:
• 400µL of buffy coat in a 2mL eppendorf was mixed with 1.6mL of
0.17M ammonium chloride and mixed by inversion until red cells
were lysed for about 10 minutes
• The cells were centrifuged at 4000rpm for 10minutes.
• The white cell pellet was washed with 800µL of 0.17M ammonium
chloride solution. The procedure was repeated till a clear white cell
pellet is obtained.
WBC Lysis
• To the pellet 500 µL of TKM I solution was added. It is
centrifuged at 10,000rpm for 10minutes.
Nuclear Lysis
• The supernatant was discarded. To the pellet 500 µL of TKM II
solution was added. To 300 µL of 6M Nacl and 50 µL of 10% SDS
was added.
• Mixed well (vortex), Centrifuged at 10,000 rpm for 10 minutes.
• The supernatant was saved and transferred to 1.5mL eppendorf.
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DNA Precipitation
• To the supernatant double the volume of 100% ethanol was added.
• The sample was stored at -20◦C for 1 hour.
• Then centrifugation at 4◦C and 10,000 rpm was done for 20minutes
using refrigerated centrifuge.
• The supernatant was discarded. To this 500 µL of 70% ethanol was
added. The pellet was mixed and centrifuged at 10,000 rpm for
10minutes at 4◦C.
• Pellet was air dried after throwing the supernatant.
Storage
30 µL of LTE buffer was added to the pellet and the extracted
DNA was stored at -20◦C for future use.
Identification
Extracted DNA was identified by 0.9% agarose gel
electrophoresis with a constant voltage of 7V/ cm and comparison with a
known molecular weight 1kb DNA ladder. Figure:14
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Figure 14
•
•
•
Concentration of extracted DNA:
• Concentration of extracted DNA was estimated using UV
spectrophotometer at 260 nm.
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• Concentration was calculated using the formula :
1 OD is equivalent to 50 µg/mL.
Conc. of DNA = absorbance X 50 µg/mL X dilution factor
= y X 50 X 100 ng/µL
• Purity of extracted DNA was assessed by 260nm/280nm.
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POLYMERASE CHAIN REACTION
SOD2 gene was amplified using,
• Forward primer – 5'GCTGTGCTTTCTCGTCTTCAG 3' and
• Reverse primer – 5'TGGTACTTCTCCTCGGTGACG3'
Primer Reconstitution
Primers were supplied in lyophilized form.
Autoclaved distilled water was used to prepare 100 × concentrations i.e.
10times the molecular weight of primer was the volume of water required
to prepare 100 × concentration which is 100µmolar solution.
• From this stock solution 10 × concentration was prepared as the
working solution for PCR.
MASTER MIX:
• Helini master mix in the following composition was used..
• Reaction buffer consisted of Tris Hcl -10mM at pH 8.3
• KCl - 50mM
• MgCl2 - 2mM acts as catalyst.
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• dNTP’s were used in a concentration of 200µM each.
• Taq polymerase in a concentration of 1.25 U.
• Primers were used in a concentration of 5 pmol and DNA was used
in a concentration of 200ng.
• The following components were mixed in a 25 µL PCR mixture.
• PCR master mix – 10.5 µL
• 5X red dye _ 2
• Forward, Reverse primer – 1 µL each
• DNA – 2µL
• Distilled H2O – 8.5 µL
• Total – 25 µL
• Amplification was carried out in an Mc Genei thermal cycler with
the following cycling conditions.
• Initial denaturation – 940 C -5min
• 30 cycles of
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• Denaturation – 940C – 1 min
• Annealing - 600C – 1min
• Extension -720C – 1min
• Final extension at 720C - 10 min.
Amplified product 267 bp by PCR was identified by 2.5% agarose gel
electrophoresis by comparison with a known 100bp DNA ladder.
Figure 15
It shows 267 bp PCR product on 2.5% agarose gel. First lane shows
100 bp ladder.
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AGAROSE GEL ELECTROPHORESIS
• PCR product was run on agarose gel in a 30 mL agarose cast as
follows: 750mg of agarose is weighed and dissolved in 30mL of
TAE buffer with a pH of 8.0.
• It was microwaved for 60 secs, cooled and 2.5 µL of ethidium
bromide (10mg/mL) was added. It was poured into a cast and
allowed to solidify for 15 min before it was kept in the
electrophoresis tank.
• 8 µL of PCR product was loaded onto wells and 4 µL of 100bp
DNA ladder was loaded onto single well as a marker. It was
electrophoresed at 7V/cm for 45min and visualized under UV
illumination.
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RESTRICTION DIGESTION
The PCR product was digested by 5U BsaWI restriction enzyme by
incubating overnight at 60 degree Celsius .
Principle of BsaWI enzyme digestion
• C allele in GCT codon does not have a restriction site and hence
will yield a 267 bp fragment.
• If T allele is present (GTT codon), a restriction site was created and
so the PCR product gets cleaved to give 184bp and 83 bp
fragments.
• Heterozygous individuals (CT genotype) will have 267 bp, 184 bp
and 83 bp fragments.
• Analysis was done using 100 bp DNA ladder.
Restriction digestion is carried out by the following protocol.
• Distilled water - 2.5µL
• 10X NE Buffer 4 - 5µL
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• BsaWI enzyme - 0.5µL(5U)
• PCR product -17µL
• Total -25µL
After overnight incubation at 60 degree celsius the digested
products were run in agarose gel electrophoresis using 2.5% LE(low
endosmosis) agarose and visualized by UV illumination. Figure16.
Figure 16
Agarose gel electrophoresis of restriction digestion fragments
after digestion with BsaW1 enzyme. Lane 1-molecular weight
marker(100-bp ladder);lanes 2,4-homozygote CC genotype; lanes 3,5-
heterozygote CT genotype; lanes 6,7,8 –homozygote TT genotype
CC CT TT
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Estimation of Fasting plasma glucose:
Method: Glucose oxidase peroxidase (GOD/POD), Enzymatic method
Principle:
Glucose oxidase
Glucose + O2 Gluconic acid + H2O2
H2O2 + Phenolic compound Peroxidase
+4aminoantipyrine Pink coloured
complex + 2H2O
The intensity of pink coloured compound is comparative to level
of glucose and analysed at a wavelength of 505nm.
Reagent composition
Glucose oxidase-20000IU/L
Peroxidase-3250IU/L
4-Aminoantipyrine-0.52 mmol/L
4-Hydroxybenzoic acid-10mmol/L
Phosphate buffer-110mmol/L
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Glucose standard-100mg/dl.
Procedure:
To 1 ml of working reagent, 10 µL of plasma was added and
placed in incubation at for 15 min at a temperature of 37°C .
Reference range: Fasting plasma glucose -→ 70 - 100 mg/dL.
Estimation of Plasma Total Cholesterol
Method
Cholesterol Esterase – Cholesterol Oxidase
Kit used
Autospan of Span Diagnostics Ltd.
Principle
Cholesterol ester is hydrolysed by cholesterol esterase to
cholesterol.the cholesterol is then acted upon by oxidase to form
cholestenone and hydrogen peroxide. The hydrogen peroxide combines
phenol and aminoantipyrine to give red coloured compound and the
measurement was done using 500nm.
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Reagents
Reagent 1 (Enzymes / Chromogen)
It contained all the enzymes and 4.aminoantipyrine.
Reagent 1A (Buffer)
It contained sodium cholate,pipes buffer and phenol.
Standard -200mg/dL
Cholesterol 2g/L
Procedure
To 1 mL of the reconstituted reagent, 10 µL of plasma was added
and reading was taken after 5 mins of incubation at 37o C.
Reference Values
Cholesterol : 150-260 mg /dL.
Estimation of Plasma Triglyceride
Method
Enzymatic Colorimetric method
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Kit Used
Autopak of Bayer Diagnostics
Principle
The triglycerides in the sample was hydrolysed by lipoprotein
lipase to givr glycerol and fatty acid. The glycerol was then acted upon by
kinase to form glycerol-3-phosphate,which is converted to hydrogen
peroxide and DHAP by oxidase. This hydrogen peroxide ,then combines
4-aminoantipyrine and ADPS to form red colour dye.
Measurement was made at 546nm.
Reagents
Reagent 1 (Enzymes / Chromogen )
It contained all the enzymes and ATP and 4-aminoantipyrine.
Reagent 1A (Buffer)
Pipes buffer. pH 7.50 50mmol/L
ADPS 1mmol/L
Magnesium salt 15 mmol/L
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Standard (Triglycerides 200mg / dL)
Glycerol (Trig.Equivalent) 2g/L
Procedure
To 1 mL of the reconstituted reagent 10 µL of plasma is added and
read at 546nm after incubation at 37oC for 5mins.
Reference Range
Males 60- 165 mg/dL
Females 40- 140 mg/dL
Estimation of HDL Cholesterol
Method Immunoinhibition
Kit used Erba XL System Packs
Principle
When anti human antibody to β-lipoprotein was added,it formed
complex with all lipoproteins except HDL.
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This HDL only can react with cholesterol oxidase and esterase
resulting in production of hydrogen peroxide. This hydrogen peroxide
then combines with F-DAOS and aminoantipyrine to form blue coloured
compound and the measurement taken at 593nm.
Anti-Lipoprotein B
antibody
LDL, VLDL & Chylomicrons antigen antibody
complex
CHE & CO
HDL-C + H2O +O2 4-cholestenone + Fatty acid + H2O2
Peroxidase
H2O2 + DAOS + 4AAP Blue colored complex + 2H2O
Reagents
Reagent 1
Goods buffer pH 7.0 30.0mmol/L
4-AAP 0.9mmol/L
POD 2400U/L
Ascorbate oxidase 2700U/L
Antihuman β lipoprotein antibody
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Reagent 2
Goods buffer, pH – 7.0 30.0mmol/L
CHE 4000U/L
CO 20000U/L
F-DAOS 0.8mmol/L
Calibrator
HDL-C 56.5mg/dL
Procedure
Reagent 1 & 2 are mixed in the ratio of 3:1 or 1 bottle of reagent 1
was mixed with 1 bottle of reagent 2 and placed in the auto analyser .
Assay type : 2 point
Primary wavelength nm : 600, Secondary wavelength nm : 700
R-1 volume : 270, R-2 volume : 90
Reaction direction : increasing, Sample volume : 3 µL
Calibration : straight
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Reference Values
Adult male : 35.3 – 79.5 mg /dL
Adult female : 42.0 – 88.0 mg / dL
VLDL and LDL Cholesterol
These parameters were calculated using Friedwald’s formula given
below:
LDL-C = TC-(HDL-C+ VLDL-C)
VLDL-C = TGL/5
Estimation of serum superoxide dismutase activity;
METHOD; Xanthine method, enzymatic method
Kit used- Fortress Diagnostics Limited
Principle ;
Xanthine oxidase in the reagent oxidizes xanthine to superoxide
and uric acid. The superoxide formed combines with I.N.T2-( 4-
iodophenyl )-3-(-4-nitrophenol)5-phenyltetrazolium chloride to produce a
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red coloured formazan dye. The superoxide dismutase in the sample
inhibits this reaction and so the decrease in intensity is measured .
xanthine oxidase
Xanthine uric acid + o2-
o2-
I.N.T Formazan dye
Reagent composition
Mixed Substrate – Xanthine(0.05mmol/l)
I.N.T.( 0.025mmol/l)
Buffer - CAPs
EDTA(0.94mmol/l)
Xanthine Oxidase - 80U/l
Standard - 4.4U/L
Sample Diluent - Phosphate Buffer pH7.00(.01mol/l)
Reagent preparation
1. Mixed Substrate (R1) 
The contents of one vial containing Mixed Substrate R1 is
reconstituted with 20 ml of Buffer R2..
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2. Buffer (R2)
Ready for use.
3. Xanthine Oxidase (R3)
one vial of R3 was reconstituted with 10ml of distilled H2O.
4. Standards (R4)
One vial of standard R4 was reconstituted with 10ml of distilled
water.
Various standers dilutions were prepared with sample diluent (R5).
The following dilutions were made of standard S6 to produce a standard
curve.
Volume of Standard Solution Volume of Sample Diluent
S6 Undiluted Standard
S5 5ml OF S6 5ml
S4 5ml OF S5 5ml
S3 5ml OF S4 5ml
S2 3ml OF S3 6ml
S1 = Sample Diluent
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Procedure ;
25 µL of diluted sample(100 times diluted with sample diluent)
was mixed with 850 µL of mixed substrate(xanthine and I.N.T) and
125µL of xanthine oxidase was added. Mixed and incubated for 30
seconds at 37 degree Celsius ,then the first reading was taken at 505nm.
Read again after 1,2 and 3 minutes.
Calculation
The mean absorbance change per minute was determined.
Activity = Asample/min x 100
As1/min
% inhibition = 100 - activity
The percentage inhibition for each standard was plotted against
Log10 (standard conc. In SOD units/ml).
A graph was drawn with percentage of inhibition of standards in
one axis and log of superoxide dismutase level in other axis.
The percentage inhibition of sample was used to obtain units of
SOD from standard curve.
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SOD units/ml of whole blood = Sod units /ml from standard curve
x dilution factor.
SOD activities are expressed as units per ml.
Reference range:
164-240U/ml.
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STATISTICAL ANALYSIS
1. Age, BMI, fasting lipid profile and plasma glucose were
compared between the 3 study groups by ANOVA.
2. Duration of diabetes, hypertension, plasma glucose, plasma lipid
profile were compared between group 1 (diabetes with CVD) and
group 2(diabetes without CVD) by t test.
3. Smoking, alcoholism and gender between 3 groups was compared
by chi square test.
4. SOD Genotype frequency (TT, CT, and CC) distribution between
cases and controls were compared with Chi square test.
5. Odds ratio was calculated for SOD genotype distribution in the
study population.
6. Allele (T, C) frequencies were calculated by allele counting.
7. SOD activity was compared between the study groups by ANOVA.
8. SOD activity for MnSOD genotypes were compared by ANOVA.
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RESULTS
MASTER CHART
Table -1 Lipid levels, BMI, genotype of Diabetic Patients with Cardiovascular Disease.
SI NO
AGE
(YR) SEX ECG
Durati
on of
DM HYT SMK ALC
WT
(KG)
HT
(m)
BMI
Kg/m2
Fasting
plasma
glucose(
mg/dl)
CHO
L
(mg/
dl)
TGL
(mg/dl)
HDL
(mg/dl)
LDL
(mg/dl)
SOD
activi
ty(U/
L)
SOD2 genotype.
1 42 M IWMI 5 Yes Yes yes 70 1.63 26.35 135 257 170 47 176 47 TT
2 40 M IWMI 6 No No yes 76 1.69 26.6 146 156 90 50 88 96 CT
3 60 F AWMI 8 Yes No No 66 1.51 28.95 124 163 110 65 76 106 CT
4 75 M IWMI 10 Yes No No 72 1.6 28.13 210 157 103 53.6 82.8 162 CT
5 55 M AWMI 6 No yes yes 78 1.6 30.47 154 245 243 60 136.4 53 TT
6 56 M AWMI 5 No No No 76 1.7 26.3 131 167 135 70 70 62 TT
7 47 M AWMI 5 No No No 78 1.6 30.47 135 170 134 72 71.2 59 TT
8 55 F AWMI 5 No No No 65 1.53 27.8 170 155 101 69 65.8 53 TT
9 46 M IWMI 6 Yes Yes No 75 1.65 27.6 181 156 145 55 72 109 CT
10 45 M AWMI 5 Yes Yes yes 81 1.63 30.45 189 167 132 67 73.6 62 TT
11 47 M IWMI 4 No Yes yes 79 1.59 31.35 208 175 146 64 81.8 47 TT
12 50 F AWMI 6 No No No 63 1.54 26.58 285 256 197 45 171.6 115 CT
13 51 F IWMI 7 Yes No No 65 1.58 26 156 287 231 46 194.8 67 TT
14 47 M AWMI 4 Yes Yes No 67 1.66 24.36 175 161 156 76 53.8 67 TT
15 48 M AWMI 4 Yes Yes yes 74 1.67 26.52 121 166 142 65 72.6 46 TT
16 50 M IWMI 5 Yes Yes yes 76 1.64 28.25 110 155 136 78 49.8 96 TT
17 45 F AWMI 6 No No No 66 1.54 27.85 95 176 145 65 82 162 CC
18 47 F AWMI 4 No No No 57 1.56 23.45 128 202 199 48 114.2 56 TT
19 55 M IWMI 7 Yes Yes No 78 1.64 29 94 209 203 54 114.4 152 CT
20 56 M IWMI 6 No No yes 73 1.6 28.51 226 170 145 78 63 56 TT
21 48 F IWMI 8 Yes No No 58 1.53 24.78 157 189 190 75 76 59 TT
22 45 F AWMI 4 Yes No No 59 1.55 24.58 151 176 145 46 101 68 TT
23 57 M AWMI 5 No Yes yes 64 1.7 22.14 142 223 190 45 140 71 TT
24 59 M AWMI 5 Yes Yes yes 81 1.71 27.7 152 245 204 68 136.2 121 CT
25 64 M AWMI 4 Yes Yes No 71 1.64 26.4 145 256 232 69 140.6 75 TT
26 65 F AWMI 5 No No No 64 1.6 25 156 188 178 52 100.4 81 TT
27 57 F AWMI 6 No No No 58 1.53 24.8 167 156 145 56 71 100 CT
28 55 M IWMI 4 No Yes No 82 1.55 34.1 158 158 134 67 64.2 87 TT
29 56 F IWMI 5 Yes No No 59 1.54 24.9 137 261 234 48 166.2 143 CT
30 57 F AWMI 4 Yes No No 66 1.57 26.5 145 186 165 53 100 90 TT
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MASTER CHART
Table -2 Lipid levels, BMI, genotype of Diabetic Patients without Cardiovascular Disease.
SI
NO
Ag
e
(Y
R
S
E
X
E
C
G
Durati
on of
diabet
es
(YR)
H
Y
T
S
M
K
A
L
C
W
T
(k
g)
HT
(m)
BMI
kg/m2
Fast
ing
plas
ma
gluc
ose
(mg/
dl)
CHO
L
(mg/d
l)
TGL(
mg/dl
)
HD
L
(mg/
dl)
LD
L(m
g/dl)
SO
D
acti
vity(
U/L)
SOD
2
Geno
type
1 40 M N 4
Y
e
s
N
o
N
o 75 1.63 28.3 156 286 245 66 171 75 TT
2 55 M N 5
Y
e
s
Y
e
s
N
o 64 1.66 23.27 124 210 90 68 124 71 TT
3 45 M N 4
Y
e
s
Y
e
s
y
e
s 78 1.51 34.2 174 170 110 72 76 122 CT
4 65 F N 4
N
o
N
o
N
o 64 1.56 26.33 97 223 103 75
127.
4 96 CT
5 66 F N 5
Y
e
s
N
o
N
o 76 1.53 32.4 113 245 231 57
141.
8 97 TT
6 70 M N 5
Y
e
s
Y
e
s
y
e
s 65 1.7 22.49 123 256 135 45 184 162 CT
7 65 M N 6
N
o
Y
e
s
y
e
s 78 1.65 28.6 228 170 203 78 51.4 206 CC
8 68 M N 8
N
o
N
o
N
o 79 1.66 28.7 96 155 101 67 67.8 97 TT
9 45 F N 4
N
o
N
o
N
o 57 1.6 22.2 146 156 145 64 63 143 CT
10 56 M N 5
N
o
N
o
y
e
s 81 1.65 29.7 154 165 132 73 65.6 121 CT
11 47 M N 4
Y
e
s
Y
e
s
y
e
s 79 1.67 28.4 152 175 234 46 82.2 100 TT
12 42 M N 5
N
o
Y
e
s
N
o 78 1.54 32.9 155 175 197 68 67.6 100 TT
13 66 M N 6
Y
e
s
Y
e
s
y
e
s 65 1.58 26.1 143 155 231 49 59.8 103 TT
14 65 F N 6
N
o
N
o
N
o 66 1.58 26.5 157 256 156 67
157.
8 200 CC
15 59 M N 6
N
o
N
o
N
o 74 1.67 26.6 168 189 142 78 82.6 115 CT
16 64 F N 4
Y
e
s
N
o
N
o 58 1.64 20.1 139 155 136 78 49.8 175 CC
17 57 M N 5
N
o
Y
e
s
y
e
s 66 1.64 24.6 157 176 145 48 99 131 CT
18 55 M N 4
N
o
N
o
N
o 57 1.58 22.89 142 202 199 50
112.
2 100 TT
19 56 F N 7
Y
e
s
N
o
N
o 56 1.55 23.4 144 209 203 65
103.
4 106 TT
20 56 F N 6
N
o
N
o
N
o 62 1.6 24.2 126 170 145 54 87 162 CC
21 45 M N 5
Y
e
s
Y
e
s
y
e
s 76 1.71 26 133 189 235 48 94 121 CT
22 48 M N 6
N
o
Y
e
s
N
o 78 1.68 27.6 212 176 145 60 87 115 CT
23 55 M N 4 Y N y 77 1.7 26.6 134 257 190 71 148 169 CC
78
e
s
o e
s
24 56 M N 5
Y
e
s
N
o
y
e
s 81 1.71 27.7 137 153 179 73 44.2 106 TT
25 47 F N 4
Y
e
s
N
o
N
o 59 1.54 24.8 175 170 197 72 58.6 162 CT
26 55 F N 6
Y
e
s
N
o
N
o 64 1.6 25 172 245 178 57
152.
4 169 CC
27 47 M N 5
N
o
N
o
N
o 58 1.6 22.6 183 157 145 68 60 115 CT
28 54 F N 10
N
o
N
o
N
o 62 1.55 25.8 187 158 134 64 67.2 106 TT
29 56 M N 8
N
o
Y
e
s
N
o 59 1.68 20.9 258 158 146 50 78.8 143 CT
30 53 F N 5
Y
e
s
N
o
N
o 57 1.57 23.1 273 186 165 53 100 143 CT
MASTER CHART
Table -3 Lipid levels, BMI, genotype of controls
SI
NO
Ag
e
(Y
R
S
E
X
E
C
G
Dura
tion
of
diabe
tes
(YR)
H
Y
T
S
M
K
A
L
C
WT
(kg)
HT
(m)
BMI
kg/m
2
Fast
ing
plas
ma
gluc
ose
(mg/
dl)
CH
OL
(mg/
dl)
TG
L(
mg/
dl)
HD
L
(mg
/dl)
LDL(
mg/dl
)
SOD
activi
ty(U/
L)
SOD
2
Gen
otyp
e
1 40 M N 4
Y
e
s
N
o
N
o 75
1.6
3 28.3 156 286 245 66 171 75 TT
2 55 M N 5
Y
e
s
Y
e
s
N
o 64
1.6
6 23.27 124 210 90 68 124 71 TT
3 45 M N 4
Y
e
s
Y
e
s
y
e
s 78
1.5
1 34.2 174 170 110 72 76 122 CT
4 65 F N 4
N
o
N
o
N
o 64
1.5
6 26.33 97 223 103 75 127.4 96 CT
5 66 F N 5
Y
e
s
N
o
N
o 76
1.5
3 32.4 113 245 231 57 141.8 97 TT
6 70 M N 5
Y
e
s
Y
e
s
y
e
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Table 1:
Table-1
Comparison of parameters in Cases and Control
Variables
CASES
Controls
Group 3
P-Value ResultsGroup1 DM with
CVD
Group 2 DM
without CVD
Age (years) 52.67±7.586 55.27±8.263 55.27±8.103 0.351 NS
BMI 27.19±2.557 26.06±3.424 26.24±2.638 0.273 NS.
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Fasting plasma
glucose
(mg/dL)
156.10±39.270 158.60±41.199 91.27±4.160 0.000 S
Cholesterol
(mg/dL)
192.93±40.56 191.57±38.421 152.10±11.158 0.000 S
TGL (mg/dL) 162.67±41.7 166.57±43.602 126.87±22.685 0.000 S
HDL (mg/dL) 60.22 ±10.854 62.8±10.545 63.367±9.661
0.459
NS
LDL (mg/dL) 100.18±39.865 95.45±38.846 63.36 ±12.192 0.000 S
Duration of
DM (years)
5.47±1.432 5.37±1.426 0.787 NS
Hypertension 16(51.6%) 15(48.4%) 0.796 NS
Sex-Male 18(32.1%) 19(33.9%) 19(33.9%) 0.954 NS
Sex-Female 12(35.3%) 11(32.4%) 11(32.4%) 0.954 NS
Smoking 13(37.1%) 11(31.4%) 11(31.4%) 0.829 NS
Alcoholism 10(33.3%) 10(33.3%) 10(33.3%) 1.000 NS
Age, BMI, Fasting lipid profile and plasma glucose were compared
between the 3 study groups by ANOVA. Male and female sex, Smoking,
alcoholism between 3 groups was compared by chi square test.
There is no significant difference between confounding factors like
age, BMI, male sex, smoking, alcoholism, HDL cholesterol between
groups.
There is significant difference in plasma glucose, triglycerides,
total cholesterol, LDL-cholesterol between cases and controls.
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Table-2
Table-2
Comparison of parameters between group1A and group 1B
Variables
CASES
P-Value ResultsGroup1A DM with
CVD
Group 1B DM
without CVD
Fasting plasma
glucose (mg/dL)
156.10±39.270 158.60±41.199 0.810 NS
Cholesterol
(mg/dL)
192.93±40.56 191.57±38.421 0.893 NS
TGL (mg/dL) 162.67±41.7 166.57±43.602 0.724 NS
HDL (mg/dL) 60.22 ±10.854
62.8±10.545 0.354
NS
LDL( mg/dL) 100.18±39.865 95.45±38.846 0.643 NS
Duration of
DM(years)
5.47±1.432 5.37±1.426 0.787 NS
Hypertension 16(51.6%) 15(48.4%) 0.796 NS
Duration of diabetes, hypertension, plasma glucose, plasma lipid
profile were compared between group 1 (diabetes with CVD) and group
2(diabetes without CVD) by t test.
There is no significant difference in duration of diabetes,
hypertension, plasma glucose, plasma lipid profile between group 1
(diabetes with CVD) and group 2(diabetes without CVD).
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From this we find that there is no significant difference in
confounding factors like age, gender, BMI, smoking, alcoholism,
duration of diabetes, hypertension, fasting plasma glucose, lipid profile
between diabetic patients with cardiovascular complications and diabetic
patients without cardiovascular complications. As all confounding factors
are matched , there is no need to perform logistic regression analysis.
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Table 3 and table 4
TABLE – 3
SOD 2 genotype distribution in study population
Genotype
Group1-
DM with CVD
30
Group2
DM without
CVD
30
Group 3
Controls
30
P value
TT 20(66.7%) 11(36.7%) 7(23.3%)
0.006-S
CT 9(30.0%) 13(43.3%) 14(46.7%)
CC 1(3.3%) 6(20.0%) 9(30.0%)
Table -4
Allele frequency and distribution of T+ allele in Diabetic CVD cases and controls
Allele
Group 1-Diabetic
CVD Cases
Controls P Value
T+ 29(97%) 21(70%) P value=0.015
T- 1(3%) 9(30%)
Shows the genotype distribution and allele frequencies of SOD2
gene in Group1 (type 2 diabetes with CVD ), Group 2 (diabetes without
CVD) and controls.
TT genotype is more frequently distributed among diabetics with
CVD 20(66.7%) compared to diabetics without CVD 11(36.7%) and
controls 1(3.3%). The difference in the frequency of TT genotype was
found to be significant between diabetic CVD cases
as indicated by the P value (0.006).
o CT and CC genotypes are distributed more in the diabetics without
CVD and in controls when
population. In short T+ genotype is more common among cases
(97%) when compared to
SOD2 genotype distribution is in agreement with the Hardy
Weinberg expectations.
Genotype distribution and allele frequency of SOD2 gene
and other two groups
compared to diabetics with CVD
controls (70%). P value is 0.015.
Figure 17
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Table 5
Univariate analysis
Allele
Group 1-Diabetic CVD
Cases
Controls Odd’s ratio
T+ 29(97%) 21(70%) Odds ratio= 12.45
(0.8-64)T- 1(3%) 9(30%)
Shows the Odds ratio calculation on Univariate analysis to evaluate
the risk of CVD among T+ genotype individuals.Odds ratio is 12.45
which implies individuals with T+ genotype have 12.45 times increased
risk of developing cardiovascular complications.
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Table 6
Table-6
SERUM SOD ACTIVITY BETWEEN STUDY GROUPS
Analyte
Group 1 A
DM with CVD
Group 1 B
DM without CVD
Group 2
Control P value
Serum SOD
activity U/L
85.60±34.843 127.70±34.771 165.43±43.792 0.000-S
Shows serum SOD activity among the three groups.
It is found that serum SOD activity for group 1(diabetics with
CVD) was 85 U/L while that of group 2(diabetics without CVD) was
127U/L and that of controls was 165U/L.
P value is 0.000, indicates that the difference is statistically
significant.
Our study results indicate that serum SOD activity is reduced in
diabetic CVD group compared to other groups.
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The SOD activity of Group 2 and Control are within the normal
range but that of Group 1 (diabetic CVD) is well reduced below lower
limit of normal.
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Serum SOD
activity U/L
DM with CVD Dm without CVD Controls
Groups
Serum SOD activity between groups
SOD activity
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Table 7
Table-7
Genotype and Phenotype (SOD activity)
Genotype SOD activity(U/L) P value
TT 85.13± 33.228
0.000-S
CT 143.92± 31.115
CC 184.12± 34.415
Shows the association of SOD genotype with the phenotype (SOD
activity)
SOD genotype and its phenotype (SOD activity) were compared.
It is observed that serum SOD activity is reduced in TT genotype.
Reduced (85U/L) level of SOD activity in TT genotype, highest
(184U/L) in CC genotype and intermediate(144U/L) in CT genotype .
TT, 85
CT, 143
CC, 184
0
20
40
60
80
100
120
140
160
180
200
SOD activity U/L
TT CT CC
SOD2 genotype
SOD activity and SOD2 genotype
SOD activity
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• P value =0.000 which is highly significant statistically. It implies
TT genotype causes reduced SOD activity.
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DISCUSSION
In this study we evaluated the association between superoxide
dismutase gene 2 Ala16Val polymorphism and cardiovascular
complications in diabetes . Hyperglycemia and increased free fatty levels
in diabetes causes elevated superoxide production in mitochondria which
is the major mechanism for cardiovascular complications. This
mitochondrial superoxide is normally dismutated by mitochondrial
superoxide dismutase. The hypothesis in this study is that polymorphism
in mitochondrial targeting sequence of manganese superoxide
dismutase gene causing reuced superoxide dismutase activity can
accelerate the development of cardiovascular complications.
From our study we found a more frequent association of TT
(val/val) genotype in diabetics with cardiovascular complications (66.7%)
when compared to controls (3.3%) and type 2 diabetics without
cardiovascular Complications (36.7%). The odds ratio for T+ allele was
found to be 12 which shows increased risk for cardiovascular
complications for those with T allele and p value (0.015) also significant.
This is similar to the study done by Milan Flekac et al, who found
positive association between the T allele of the MnSOD gene
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polymorphism and diabetic cardiovascular complications in Prague,
Czech Republic .
There are no significant differences in confounding factors like age,
sex, BMI, smoking, alcoholism, hypertension, plasma triglycerides, LDL-
cholesterol between diabetics with cardiovascular complications and
diabetics without cardiovascular complications.
In our study we found that serum superoxide dismutase activity
was reduced in the diabetics with cardiovascular complications, with the
mean value of 85 U/L while that of diabetics without cardiovascular
complications group, it was 127U/L and that of controls was 165U/L. The
difference was found to be statistically significant (P value=0.000)
between diabetics with and without cardiovascular complications and
between cases and controls.
We found that individuals with TT (val/val) genotype have lower
serum superoxide dismutase activity than those with CC (ala/ala) and CT
(ala/val) genotype. This may be due to alteration of conformation of
mitochondrial targeting sequence from α helix (present in those with C
allele) to β sheets (present in those with T allele) which leads to reduced
import of MnSOD enzyme in to mitochondria and degradation by
proteosome 114,.. Similar findings were found by Hirori et al and Robert
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C.G. Martin et al . This may show that ala 16 val MnSOD gene
polymorphism determines the level of mitochondrial superoxide
dismutase activity and in turn serum level of superoxide dismutase.
These studies indicate that T (val) allele is associated with
oxidative stress where as C(Ala) allele protects against oxidative stress.
But contrasting findings have been found in various diseases associated
with oxidative stress as follows.
Studies done in American and Finland population had shown
positive association of alanine genotype with carcinoma of the breast 87,.
Another study conducted at Taiwan found that individuals with alanine /
alanine genotype were more prone for psoriatic arthritis 88 . Positive
relation between alalnine genotype and sporadic motor neuron disease
was found by study by Van Landeghem et al., 1999a .
A positive association between alanine/alanine genotype and age
related macular degeneration was found in study conducted by Kimura
et al., 2000,89 , Shimoda-Matsubayashi et al., 1996 also found increased
frequency of ala allele in Parkinson’sdisease 10. All these diseases which
are mainly caused by oxidative stress show increased frequency of C
allele except for one study which showed association of T (val) allele
with lung cancer 90.
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But all the studies of MnSOD gene polymorphism associated with
diabetes show positive association of T allele with complications.
Though alanine allele had been found to be associated with cancers
in various studies, it had been observed as a protective allele against
micro and macrovascular complications in diabetes. For example, a study
conducted in USSR by Dimitry A Chistyakov et al 91 found that valine
allele was more frequent in diabetic patients with nephropathy than
alanine allele. Similar findings were found in studies conducted at Japan
and korea,92.
Study done by Jones DA in Caucasian population among diabetic
patients found a positive link between reduced level of superoxide
dismutase and coronary heart diseae 93 . Sakari Kakko et al found a
positive link between this alanine 16 valine manganese superoxide
dismutase polymorphism and degree of atherosclerosis in carotid artery.94
The present study has shown increased distribution of TT
genotype and reduced level of serum superoxide dismutase activity in
diabetic patients with cardiovascular complications.
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CONCLUSION
The present study was done to find out the SOD2 gene (T>C)
substitution polymorphism among diabetics with cardiovascular disease
and without cardiovascular disease. 30 cases of diabetics with
cardiovascular disease were compared with 30 diabetics without
cardiovascular disease.
From our study we found that
1. Type 2 diabetics with cardiovascular disease had a higher
frequency of SOD2 TT genotype compared to diabetics without
cardiovascular disease and controls.
2. There is a significant difference in TT genotype between diabetics
with cardiovascular disease and diabetics without cardiovascular
disease.
3. Serum SOD activity is significantly reduced in Diabetics with
cardiovascular disease which may be responsible for
cardiovascular complications.
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4. The level of Serum SOD activity was lowest in TT genotype, and
highest in CC genotype and hence TT genotype is strongly
associated with cardiovascular disease.
As all the confounding factors are matched, TT genotype is an
independent risk factor for the development of cardiovascular
complications.
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FUTURE PROSPECTS OF THE STUDY
1. Methods to accurately quantify the level of mitochondrial MnSOD
activity in leukocytes and correlating them with cardiovascular
complications in diabetes can be performed.
2. Trails of SOD mimetic compounds to diabetic patients and their
follow up for development of complications may be tried.
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Limitations of the study
Since mitochondrial superoxide dismutase(SOD2) contributes only
little to the amount of serum level of the enzyme superoxide dismutase, it
would have been accurate if mitochondrial superoxide dismutase was
measured in mitochondria of leukocytes by differential centrifugation.
But as, extraction of mitochondria and its lysis requires centrifugation at
very high speed (25,000 rpm ) it was not possible to perform in our lab.
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PATIENT CONSENT FORM
Title of the study : “SUSCEPTIBILITY OF DIABETICS WITH
SUPEROXIDE DISMUTASE GENE 2 POLYMORPHISM TO
VASCULAR COMPLICATIONS ”
Name : Date :
Age : OP No :
Sex : Project Patient No :
The details of the study have been provided to me in writing and
explained to me in my own language.
I confirm that I have understood the above study and had the opportunity
to ask questions.
I understand that my participation in the study is voluntary and that I am
free to withdraw at any time, without giving any reason, without the
medical care that will normally be provided by the hospital being affected.
I agree not to restrict the use of any data or results that arise from this
study provided such a use is only for scientific purpose(s).
I have been given an information sheet giving details of the study.
I fully consent to participate in the above study.
Signature
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SUSCEPTIBILITY OF DIABETICS WITH SUPEROXIDE
DISMUTASE GENE 2 POLYMORPHISMS TO VASCULAR
COMPLICATIONS.
PROFORMA
Name: Age/Sex: IP /OP No:
Address: Phone No:
Ward
Diagnosis:
Presenting complaints: Duration:
Past history:
Chest pain
Stroke
Peripheral neuropathy
Diabetic foot
Vision problems
Renal disease
Personal History:
Smoking
Alcoholism
Tobacco chewing
Menstrual history
No.
122
Diet history
Family history
Examination :
Vital data :
Heart Rate :
Blood pressure (mean) :
Height :
Weight :
Systemic examination :
CVS
RS
ABDOMEN
CNS
PNS
Impression
Investigations:
Fasting plasma glucose
Fasting serum superoxide dismutase level
Fasting lipid profile
Superoxide dismutase gene 2 polymorphism-RFLP PCR,3%agarose
gel electrophoresis.
ECG
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ANTIPLAGIARYSIM CHECK
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